AstraZeneca to co-promote J&J's Zytiga in Japan

Johnson & Johnson (NYSE:JNJ) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) rights to co-promote Zytiga abiraterone acetate in Japan. J&J submitted a regulatory application in July to Japan's Ministry of Health, Labor and Welfare (MHLW) for Zytiga to treat prostate cancer. The pharmas declined to disclose financial details. ...